Memantine (Namenda) for Moderate to Severe Alzheimer's Disease

American Family Physician

Volumn 69, Issue 6, 2004, Pages 1491-1492

  Ables, Adrienne Z ^a  

^a Spartanburg Fam Med Residen Prog ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER;

AGITATION; ALZHEIMER DISEASE; CONFUSION; CONSTIPATION; DEGENERATIVE DISEASE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; NERVE CELL LESION; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE;

ALZHEIMER DISEASE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 1642277866     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Forest Pharmaceuticals, Inc. Namenda package insert. St. Louis, Mo: October, 2003. Accessed online January 30, 2004, at: http://www.namenda.com/pdf/namenda_pi.pdf.
2. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev. 2003;(4):CD003154.
3. Facts: about memantine, an experimental Alzheimer's drug. Alzheimer's Association 2003. Accessed online January 30, 2004, at: http://www.alz.org/resourcecenter/bytopic/memantine.htm.
4. Reisberg B, Doddy R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
5. Tariot PN, Farlow MR, Grossberg CT, et al. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil. A randomized controlled trial. JAMA 2004;291:317-24.
6. Memantine for Alzheimer's disease. Med Lett Drugs Ther. 2003;45:73-4.